New research indicates that people who come off popular GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass far faster than those who end conventional diet and exercise plans.
Published data in a major health publication demonstrates that while overweight people frequently drop substantial amounts of their total mass while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying such medications should be aware of the risk of fast weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment mass in about 18 months.
Weighing Approaches
The study, which examined dozens of trials involving thousands of participants, contrasted the effects of these new drugs with conventional dieting.
Scientists point out that people who lose weight through lifestyle changes alone generally experience a slower weight regain—around 100 grams monthly—post-intervention.
The Reason for the Quick Rebound
Experts suggest the mechanism of the injections is key to understanding the accelerated weight return.
These medications copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal could lead to the system to generate a reduced amount of its endogenous hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication results in appetite is uncontrolled, making overeating far more likely."
An Ongoing Condition?
Health authorities recommend the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals say that, given the likelihood of relapse, the treatment is often long-term.
This opinion is reinforced by drug manufacturers, who say that the results "highlight the persistent character of obesity," similar to managing diseases like high blood pressure.
User Accounts
Users who have stopped the jabs report a powerful return of hunger.
"It was like a switch flipping and I was suddenly ravenous," described one woman.
This challenge is worsened if patients have not adopted sustainable dietary or behavioural changes during therapy.
Significant Adoption
Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is more common among women compared to men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, clinicians caution that while the jabs are powerful agents for shedding pounds, they are not a standalone cure and lasting health benefits relies on ongoing behavioural support.
